Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders

Dawn Eggert, Prasanta K. Dash, Nawal Serradji, Chang Zhi Dong, Pascal Clayette, Francoise Heymans, Huanyu Dou, Santhi Gorantla, Harris A. Gelbard, Larisa Poluektova, Howard E. Gendelman

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


The neuroregulatory activities of PMS-601, a platelet activating factor antagonist, were investigated in laboratory and animal models of HIV-1 encephalitis (HIVE). For the former, PMS-601 reduced monocyte-derived macrophage pro-inflammatory secretions, multinucleated giant cell (MGC) formation, and neuronal loss independent of antiretroviral responses. PMS-601 treatment of HIVE severe combined immunodeficient mice showed reduced microgliosis, MGCs and neurodegeneration. These observations support the further development of PMS-601 as an adjunctive therapy for HIV-1 associated neurocognitive disorders.

Original languageEnglish (US)
Pages (from-to)47-59
Number of pages13
JournalJournal of Neuroimmunology
Issue number1-2
StatePublished - Aug 18 2009


  • Human immunodeficiency virus
  • Multinucleated giant cell
  • Nuclear factor kappa beta
  • PMS-601
  • Platelet activating factor
  • Proline-rich tyrosine kinase 2

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders'. Together they form a unique fingerprint.

Cite this